Albert Jang, MD (@ajangmd) 's Twitter Profile
Albert Jang, MD

@ajangmd

Fellow @cwruhemeonc @caseccc @UHhospitals. Former IM chief resident @TulaneDDOM @VANewOrleans. Aspiring GU medical oncologist. Avid sports fanatic.

ID: 1495616703912419328

calendar_today21-02-2022 04:29:48

116 Tweet

388 Followers

344 Following

Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Just in Journal of Clinical Oncology 👉Final OS analysis of SWOG Cancer Research Network 1500 trial 👉 data support cabozantinib for treatment of advanced papillary RCC #kidneycancer (unless clinical trials are available). Free access paper 👉 tinyurl.com/2s3t7z27 Congrats Pedro C Barata, MD MSc FACP & Sumanta K. Pal, MD, FASCO & authors Naomi Haas

Just in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> 👉Final OS analysis of <a href="/SWOG/">SWOG Cancer Research Network</a> 1500 trial 👉 data support cabozantinib for treatment of advanced papillary RCC #kidneycancer (unless clinical trials are available). Free access paper 👉 tinyurl.com/2s3t7z27 Congrats <a href="/PBarataMD/">Pedro C Barata, MD MSc FACP</a> &amp; <a href="/montypal/">Sumanta K. Pal, MD, FASCO</a> &amp; authors <a href="/NaomiHaas5/">Naomi Haas</a>
Laura Bukavina (@laurabukavinamd) 's Twitter Profile Photo

Serial ctDNA monitoring in met RCC Patients with serial ctDNA - or clearance had a 3.2x ⬇️ risk of progression during tx. Where it really shines ⭐️is off tx surveillance, ctDNA+ patients had 18x ⬆️⬆️ risk of progression #CancerBiomarker Natera ascopubs.org/doi/full/10.12…

Serial ctDNA monitoring in met RCC Patients with serial ctDNA - or clearance had a 3.2x ⬇️ risk of progression during tx. Where it really shines ⭐️is off tx surveillance, ctDNA+ patients had 18x ⬆️⬆️ risk of progression  #CancerBiomarker <a href="/NateraGenetics/">Natera</a> ascopubs.org/doi/full/10.12…
Albert Jang, MD (@ajangmd) 's Twitter Profile Photo

Fighting through sleep deprivation and the fire hydrant of GU onc knowledge, beginning with OncLive.com Fellows Forum on Wednesday to last through this final day of ASCO #GU25 with the Cleveland, Salt Lake City and Boston team! Until #GU26... No ☕ for me 😁

Fighting through sleep deprivation and the fire hydrant of GU onc knowledge, beginning with <a href="/OncLive/">OncLive.com</a> Fellows Forum on Wednesday to last through this final day of <a href="/ASCO/">ASCO</a> #GU25 with the Cleveland, Salt Lake City and Boston team! Until #GU26...

No ☕ for me 😁
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 (@cparkmd) 's Twitter Profile Photo

⭐️Future of GU oncology is VERY bright. LOVED learning about the cutting edge research of the Fellows and trainees at OncLive.com GU Fellows forum at #GU25. Also really enjoyed joining global GU leaders and superb mentors Dr. Choueiri Dr. McKay and Dr. Garcia as they provided

⭐️Future of GU oncology is VERY bright.  LOVED learning about the cutting edge research of the Fellows and trainees at <a href="/OncLive/">OncLive.com</a> GU Fellows forum at #GU25.  Also really enjoyed joining global GU leaders and superb mentors Dr. Choueiri Dr. McKay and Dr. Garcia as they provided
TwoOncDocs (@twooncdocs) 's Twitter Profile Photo

Thank you all who joined Clinicals to Exams & guest appearance w/ baby Cary A few high-yield mnemonics: 🌟 ribociclib - “ribs” close to ❤️- Qtc; abemaciclib - “abs” - diarrhea 🌟 tumor marker half-life: Hcg -3 letters, 1-3d; AFP -alpha - 5 letters 5-7d Ready for #ASCO25 day 1!

Thank you all who joined Clinicals to Exams &amp; guest appearance w/ baby Cary

A few high-yield mnemonics:
🌟 ribociclib - “ribs” close to ❤️- Qtc; abemaciclib - “abs” - diarrhea
🌟 tumor marker half-life: Hcg -3 letters, 1-3d; AFP -alpha - 5 letters 5-7d 

Ready for #ASCO25 day 1!